For instance, it has been previously demonstrated that local delivery of adjuvants such as CpG (type B) initiates in situ immunization, and combining anti-OX40 ICM with intratumoral CpG (type B) administration abrogates tumor growth and protects mice from tumor rechallenge (51). Here, TNFRSF4 is linked to neoplasm.